ASH 2018 | Quizartinib provides clinical benefit in R/R FLT3-ITD AML

Mark Levis

Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the Phase III Quantum-R trial (NCT02039726) of the FLT3 inhibitor quizartinib for relapsed/refractory acute myeloid leukemia (AML). This confirmed the clinical benefit of quizartinib monotherapy vs. salvage chemotherapy in this patient group; and now an approval in this space is looking ever more likely. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video